FDA Finalizes Interchangeable Biosimilar Advice, with Insulin Focus
May 13, 2019
Andrew Dunn
BioPharma Dive
Axinn partner Stacie Ropka was quoted in the BioPharma Dive article, "FDA Finalizes Interchangeable Biosimilar Advice, with Insulin Focus."
Click here to access the article.